SOX/XELOX

DRUG3 trials

Sponsors

Lin Chen, Xiangdong Cheng, The First Affiliated Hospital with Nanjing Medical University

Conditions

EfficacyGastric CancerHER2 NegativeLocally Advanced Gastric CarcinomaSafetyStomach Neoplasms

Phase 2

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

RecruitingNCT06284746

Lin ChenEfficacy, HER2 Negative, Locally Advanced Gastric Carcinoma +1

Start: 2023-10-01End: 2025-07-30Target: 80Updated: 2024-02-29

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Not yet recruitingNCT06374901

Xiangdong ChengGastric Cancer

Start: 2024-04-25End: 2028-03-31Target: 134Updated: 2024-04-19

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Not yet recruitingNCT06564298

The First Affiliated Hospital with Nanjing Medical UniversityStomach Neoplasms

Start: 2024-08-31End: 2026-06-30Target: 39Updated: 2024-08-28

Related Papers

Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial.

2026-07-15

Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC: A prospective, randomized, open-label, biomarker-driven, phase 2 trial.

Journal of Clinical Oncology2026-05-27